Bacterial Toxin Research Citations

July 24, 2024

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie

Zhang, YL;Qu, Y;Song, HH;Cheng, G;Lu, F;Cui, TT;Gong, Y;Ding, XL;Yang, Y;Zhang, Q;Yang, LT;Yan, YP;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

plete Freund's adjuvant (CFA, Sigma, US) containing 5?mg/mL of Mycobacterium tuberculosis H37Ra (231141 Dessicated, BD, Difco, US). This emulsion was subcutaneously injected (s.c.) into the neck and back of the mice on day 0. Subsequently, a total of 200?ng of pertussis toxin (PT, List Biologic, Campbell, CA, US) was administered intraperitoneally (i.p.) to the mice on days 0 and 2 following immunization. Mice were randomly divided into two groups: the EAE+Vehicle and EAE+ILG groups. To evaluate the therapeutic impact of ILG on EAE, the EAE+ILG group was further stratified into two sub-groups: EAE+ILGprevent (ILG administered starting on day 2) and EAE+ILGtreatment (ILG first administered on day 12, when the clinical scores of EAE mice were approximately 0.5) as depicted in Fig. 1 B

July 23, 2024

Biorxiv

Mazzone, R;Winsor, N;Li, L;Barry, K;Ranger, A;Goyal, S;Meade, J;Bruce, J;Philpott, D;Mogridge, J;Girardin, S;

Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis

illipore Sigma), 5z7 (Sigma-Aldrich), LF (List Labs), Ifn-? recombinant mouse protein (Thermo Fisher), recombinant mouse IL-22 protein (R&D Systems), recombinant murine IL-13 (Peprotech), recombinant murine TNF-? (Peprotech), standard flagellin from Salmonella typhimurium (Invivogen), and Val-Boro-Pro (Sigma

July 23, 2024

Cell Reports

Liu, X;Liu, K;Wang, Y;Meng, X;Wang, Q;Tao, S;Xu, Q;Shen, X;Gao, X;Hong, S;Jin, H;Wang, JQ;Wang, D;Lu, L;Meng, Z;Wang, L;

Product: Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free)

ulosis (BD, 231143). In addition, the mice were administrated 200 ng of Pertussis toxin (List Biological Laboratories, 181) intravenously (i.v.) on days 0 and 2. The severity of EAE was monitored and graded in a blinded fashion on a clinical score of 0-5: 0, no clinical signs; 1, limp tail; 2, paraparesis (weakness, incomplete paralysis of one or two hind limbs); 3, paraplegia (compl

July 22, 2024

Biorxiv

Ramamurthy, D;Rodriguez, L;Cen, C;Li, S;Chen, A;Feldman, D;

Product: Botulinum Neurotoxin Type A from Clostridium botulinum

Botox injection to induce paralysis of whisking43,85-87. Both whisker pads were injected with Botox (Botulinum Neurotoxin Type A from Clostridium botulinum, List Labs #130B). A stock solution of 40 ng/?l Botox was prepared with 1mg/ml bovine serum albumin in distilled water. Each whisker pad was injected with 1 ?l of a 10 pg/?l final dilution using a microliter syringe (Hamilton). Whisking stopped within

July 22, 2024

Biorxiv

Flierman, N;Koay, S;van Hoogstraten, W;Ruigrok, T;Roelfsema, P;Badura, A;De Zeeuw, C;

Product: Anti-Cholera Toxin B Subunit (Goat)

peroxidase activity of blood. Next, the sections were blocked in 10% normal horse serum (NHS) in PBS with 0.5% triton, after which they were incubated at room temperature with anti-CTb (goat, 1:15000, List labs) primary antibody (in PBS with 2% NHS, 0.5% triton) for 48-72 hrs and next with biotinylated rabbit anti-goat (1:200, Vector) secondary antibody (also in PBS with 2% NHS and 0.5% triton) for 1.5 hrs. After washing with PBS, the sections were incubated in Avidin-Biotine complex (1:200 Avidine and Biotine, Vector) in PBS and 0.5% triton

July 22, 2024

Microbes And Infection

Mazzone, RJ;Winsor, NJ;Li, LY;Barry, KT;Ranger, A;Goyal, S;Meade, JJ;Bruce, J;Philpott, DJ;Mogridge, J;Girardin, SE;

Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis

1G244 (Millipore Sigma), 5z7 (Sigma-Aldrich), LF (List Labs), Ifn-? recombinant mouse protein (Thermo Fisher), recombinant mouse IL-22 protein (R&D Systems), recombinant murine IL-13 (Peprotech), recombinant m

July 20, 2024

Journal Of Neurochemistry

McDougall, SJ;Ong, ZY;Heller, R;Horton, A;Thek, KK;Choi, EA;McNally, GP;Lawrence, AJ;

Product: Cholera Toxin B Subunit (Choleragenoid) from Vibrio cholerae in Low Salt

3% isoflurane in air as necessary. The retrograde tracers using a Picospritzer; cholera toxin B subunit (CTb, 20-80?nL, 1% in distilled water; List Biological Laboratories; RRID:AB_10013220) or Red Retrobeads (100?nL, Lumafluor Inc.) were unilaterally or bilaterally injected into the NAc shell: bregma +0.12?mm AP, ±0.07?mm ML, ?0.48?mm DV. Mice were administered meloxica

July 19, 2024

Cellular & Molecular Immunology

Lin, B;Zhou, Y;Huang, Z;Ma, M;Qi, M;Jiang, Z;Li, G;Xu, Y;Yan, J;Wang, D;Wang, X;Jiang, W;Zhou, R;

Product: Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free)

l Fast Blue (Sigma, L0294, MCKF3315), DAPI (Sigma, D9542), DNase I (Sigma, DN25), pertussis toxin (List Biological, #181), Freunds Incomplete Adjuvant (Difico, 263910, 8008624), mycobacterium tuberculosis (Difico, 231141, 9347411) and Tamoxifen (MCE, HY-13757A), OptiPrep (Sigma, D1556), Hibernate A (Thermo fisher, A1247501), L-Glutamine (Thermo fisher, 250

July 18, 2024

European Journal Of Immunology

Iijima, N;Hayashi, T;Niino, M;Miyamoto, Y;Oka, M;Ishii, KJ;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

nds were diluted in PBS to 0.01%, 0.5%, or 0.9%, respectively. All emulsions or mixtures were then injected s.c. into the flank skin of mice on days 0 and 7 for the 2×MOG immunization. In addition, pertussis toxin (PTX; 0.2 ?g/mouse; 181; List Biological Laboratories, Inc.) was injected i.v. on days 0, 2, and 7. Alternatively, immunization with PLP1

July 17, 2024

Biorxiv

Goor, I;Altman, E;Arman, I;Haus-Cohen, M;Reiter, Y;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

s with 0.2 ml of an emulsion of 100-200 ?g immunogenic peptide and complete Freunds adjuvant containing 400 ?g of heat-killed Mycobacterium tuberculosis H37RA (Difco, Detroit, MI). In addition, mice were given pertussis toxin (Ptx) from List Biological Laboratories (Campbell, CA) on days 0 and 2 post- immunization (2* 200 ng per mouse). Immunized mice were assessed daily for clinical signs of EAE on a 5-point scale: 0 - Clinically normal, 1 - Decreased tail tone or weak tail only, 2 - Hind limb weakness

Bacterial Toxin Research Citations

Isoliquiritigenin alleviates experimental autoimmune encephalomyelitis by modulating inflammatory and neuroprotective reactive astrocytes

NLRP1B allele 2 does not respond to Val-boro-Pro (VbP) in the intestinal epithelium

SWI/SNF chromatin remodeling factor BAF60b restrains inflammatory diseases by affecting regulatory Tcell migration

Reward history cues focal attention in whisker somatosensory cortex

Encoding of cerebellar dentate neuronal activity during visual attention in rhesus macaques

NLRP1B expressed in intestinal epithelial cells is refractory to activation with Val-boro-Pro

Viscerosensory signalling to the nucleus accumbens via the solitary tract nucleus

GPR34 senses demyelination to promote neuroinflammation and pathologies

Tridecylcyclohexane in incomplete Freund’s adjuvant is a critical component in inducing experimental autoimmune diseases

Antigen-Specific modulation of Chronic Experimental Autoimmune Encephalomyelitis in Humanized Mice by TCR-like Antibody Targeting Auto-Reactive T-Cell Epitope